Abstract This study presents the hypothesis that triosephosphate isomerase (TIM), a pivotal enzyme in glycolysis, functions as a quantum logic gate. Utilizing quantum mechanics, we model TIM’s catalytic conversion of dihydroxyacetone phosphate (DHAP) to glyceraldehyde-3-phosphate (G3P) as a quantum operation involving precise proton transfer. To explore the broader implications of this quantum behavior, we developed a quantum model to assess the impact of Sodium-glucose co-transporter 2 inhibitors (SGLT2i) on methylglyoxal formation, a toxic byproduct linked to advanced glycation end products (AGEs). Our model predicts that SGLT2i could reduce methylglyoxal by decreasing the likelihood of intermediate formation, providing a potential mechanism for their protective effects observed in clinical contexts, including vascular and renal protection in diabetes, nephropathy, and heart failure. By reframing TIM as a quantum logic gate, this study not only challenges traditional views of enzymatic function but also opens new avenues for quantum biology, offering profound implications for the future of metabolic disease research and drug development. Moreover considering methylglyoxal as a result of a quantum tunnel inefficiency, it’s possible to hypothesize a new “noxa patogena” explicating it’s action as quantum interference.
Abstract This study presents the hypothesis that triosephosphate isomerase (TIM), a pivotal enzyme in glycolysis, functions as a quantum logic gate. Utilizing quantum mechanics, we model TIM’s catalytic conversion of dihydroxyacetone phosphate (DHAP) to glyceraldehyde-3-phosphate (G3P) as a quantum operation involving precise proton transfer. To explore the broader implications of this quantum behavior, we developed a quantum model to assess the impact of Sodium-glucose co-transporter 2 inhibitors (SGLT2i) on methylglyoxal formation, a toxic byproduct linked to advanced glycation end products (AGEs). Our model predicts that SGLT2i could reduce methylglyoxal by decreasing the likelihood of intermediate formation, providing a potential mechanism for their protective effects observed in clinical contexts, including vascular and renal protection in diabetes, nephropathy, and heart failure. By reframing TIM as a quantum logic gate, this study not only challenges traditional views of enzymatic function but also opens new avenues for quantum biology, offering profound implications for the future of metabolic disease research and drug development. Moreover considering methylglyoxal as a result of a quantum tunnel inefficiency, it’s possible to hypothesize a new “noxa patogena” explicating it’s action as quantum interference.
• Published on bioRxiv, presenting a biophysical hypothesis that models triosephosphate isomerase (TIM), an enzyme essential for cellular glucose metabolism, as a quantum logic gate. • Predicted through a quantum mechanical model that SGLT2 inhibitors (SGLT2i), a diabetes treatment, reduce the probability of quantum decoherence in the TIM enzyme reaction. • Pioneering a new research frontier of quantum pharmacology by preventing the production of methylglyoxal, a cytotoxic byproduct, through the suppression of decoherence. [Quantum Biology Society] Groundbreaking biophysical research has been published revealing that an enzyme essential for cellular glucose metabolism (glycolysis) virtually operates like a quantum logic gate, the computational unit of a quantum computer. Going beyond classical biochemistry, this is a milestone achievement interpreting the human protective mechanisms of metabolic disease treatments from the perspective of subatomic quantum information processing. A paper titled "Triosephosphate Isomerase as a Quantum Logic Gate: Could quantum decoherence be toxic?" was released on the preprint repository bioRxiv. A joint research team of Daniele Romanello, a physician in Internal Medicine at Ospedale San Pietro Fatebenefratelli in Rome, Italy, and Andrea Romanello from the Department of Information Engineering at Sapienza University of Rome proposed this innovative quantum medical model. ■ Enzyme Catalysis Interpreted as Quantum Computation The researchers focused on the catalytic process of triosephosphate isomerase (TIM), a key enzyme in glycolysis, converting dihydroxyacetone phosphate (DHAP) to glyceraldehyde-3-phosphate (G3P). Instead of viewing this process merely as a classical "lock-and-key" model where specific molecular structures fit together, they remodeled it as a highly advanced quantum computational workflow involving precise proton transfer. This implies that enzymes in vivo act as logic circuits that autonomously control quantum states to derive specific biochemical outcomes. ■ SGLT2 Inhibitors Protect Cells by Preventing Quantum Decoherence What is even more interesting is that this quantum model interpreted the hidden human protective effects of sodium-glucose co-transporter 2 inhibitors (SGLT2i), which are widely prescribed as treatments for heart failure and diabetes. According to the model's predictions, if quantum decoherence occurs—where the enzyme loses its quantum state due to interference from the external environment during the metabolic process—it produces methylglyoxal, a toxic byproduct that destroys cells and strongly accelerates aging. As a result of the researchers' analysis, SGLT2i drugs were found to significantly reduce the probability of quantum decoherence in this TIM enzyme reaction. In other words, by suppressing the noise in the intracellular quantum computation process, the drug dramatically lowers the accumulation of the highly toxic substance methylglyoxal, ultimately exerting a powerful organ-protective effect. ■ The Prelude to the Era of Quantum Pharmacology This study holds great significance in that it reinterprets the pathogenesis of diseases and the mechanism of drug action beyond molecular chemical bonds, from the perspective of quantum coherence and dynamics. Experts anticipate that this approach will serve as an excellent starting point for quantum pharmacology, bringing a fundamental paradigm shift to the design of next-generation drugs for treating metabolic syndrome and degenerative diseases.
• Raised the hypothesis that 'TIM', a pivotal enzyme in cellular glycolysis, functions as a 'quantum logic gate' beyond a simple chemical catalyst. • Elucidated that upon the occurrence of quantum decoherence, methylglyoxal, a toxic substance causing diabetic complications, is produced. • Reinterpreted the root cause of metabolic diseases as a 'failure of quantum interference', and demonstrated the protective effects of SGLT2 inhibitors through a quantum model. [Quantum Biology Society] Groundbreaking research results have emerged suggesting that metabolic enzymes, which generate energy in our bodies, operate not merely as simple chemicals, but like 'quantum logic gates', the computational units of quantum computers. Recently, a paper titled "Triosephosphate Isomerase as a Quantum Logic Gate: Could quantum decoherence be toxic?" was published on bioRxiv, a preprint repository for biology. This study is drawing extraordinary attention from the medical community by reinterpreting the pathogenesis of diseases from a quantum mechanical perspective, going beyond classical biochemistry. ■ A Key Enzyme in Life Phenomena Operates as a 'Quantum Logic Gate' The research team focused on the operational mechanism of 'triosephosphate isomerase (TIM)', a pivotal enzyme in cellular glycolysis that breaks down glucose into energy. The researchers modeled the precise proton transfer process occurring within the enzyme as a 'quantum tunneling' action rather than a simple chemical catalytic reaction. This is an unconventional hypothesis that the TIM enzyme functions like a 'quantum logic gate', the fundamental unit of a quantum computer, to control the conversion of substances with extreme precision. ■ Quantum Errors (Decoherence) Create 'Toxicity' The most surprising discovery is what happens when inefficiencies arise due to the so-called 'quantum decoherence' phenomenon during this quantum tunneling process. The study showed that when an error occurs in the computation (catalysis) as the quantum state breaks down, a fatal toxic byproduct called 'methylglyoxal' is produced instead of normal metabolites, inducing the formation of advanced glycation end products (AGEs) that cause diabetic complications. In other words, a 'quantum mechanical malfunction' (failure of quantum tunneling) of metabolic enzymes in cells can be the direct cause of metabolic disease complications. ■ The Efficacy of the Diabetes Drug 'SGLT2 Inhibitors' Proven by a Quantum Model... A New Paradigm in Drug Development Furthermore, the research team developed a mathematical quantum model of how 'SGLT2 inhibitors', a widely used diabetes treatment, protect the body. As a result of simulation analysis through a Python script, it was confirmed that this drug exerts a protective effect on vascular and renal cells by lowering the probability of the formation of the toxic intermediate (methylglyoxal). This approach is highly significant in that it reinterpreted the root cause of metabolic diseases, including diabetes, as a problem at the level of 'quantum interference' rather than a simple chemical imbalance. This research, which identified the causes of diseases from a quantum mechanical perspective and theoretically proved the efficacy of drugs, is expected to provide a strong foundation for the development of new metabolic disease drugs with novel mechanisms that fundamentally block the generation of toxic byproducts in the future.
Abstract Context Proton transfer in drug–protein cavities is central to enzymatic catalysis and pH-responsive drug delivery, yet classical models often fail to capture the quantum mechanical behavior that governs these processes. The influence of nanoscale confinement on proton dynamics through quantum effects remains poorly understood, limiting our ability to design optimized therapeutic systems. We present a quantum theoretical framework that connects cavity geometry with measurable proton transfer properties, offering new insights for biocatalysis and nanomedicine. Method We developed an analytical model for proton confinement in biological cavities by solving the Schrödinger equation for two spherically symmetric potentials: finite square wells representing hydrophobic environments and Morse potentials for hydrogen-bonded systems. Our approach systematically calculates ground-state energies, wavefunctions, tunneling probabilities, and vibrational overtones. Results show confinement geometry exponentially modulates proton behavior, with tunneling probabilities spanning > 12 orders of magnitude under physiological conditions. Kinetic isotope effects (> 10¹¹) and catalytic enhancements (10³-fold) confirm quantum tunneling dominance. While finite wells promote classical localization, Morse potentials enable efficient proton transfer through delocalization. The model incorporates environmental decoherence and establishes design rules linking cavity parameters to spectroscopic and kinetic signatures, providing a bridge between quantum theory and structural biology.
In the emerging field of quantum biology, we begin to see how biological systems exploit quantum mechanics as their efficiency and certain phenomena such as photosynthesis and enzymatic reactions cannot be explained only by classical physics. This paper will shortly review the foundations and axioms of quantum mechanics including wave particle duality, Heisenburg's uncertainty principle and the probabilistic interpretation of a wave function before exploring the first primary topic-quantum tunneling in enzymes. The paper will then provide deeper insights into quantum effects in photosynthesis including coherence, entanglement and the photoelectric effect. Additionally, quantum biology will have profound implications on the future of quantum technology. Leveraging the information scientists have gained about the quantum mechanical functions of biological systems, this paper will delve into the applications of this know-how in quantum technology.
Abstract The role of proton tunnelling in biological catalysis is investigated here within the frameworks of quantum information theory and thermodynamics. We consider the quantum correlations generated through two hydrogen bonds between a substrate and a prototypical enzyme that first catalyses the tautomerization of the substrate to move on to a subsequent catalysis, and discuss how the enzyme can derive its catalytic potency from these correlations. In particular, we show that classical changes induced in the binding site of the enzyme spreads the quantum correlations among all of the four hydrogen-bonded atoms thanks to the directionality of hydrogen bonds. If the enzyme rapidly returns to its initial state after the binding stage, the substrate ends in a new transition state corresponding to a quantum superposition. Open quantum system dynamics can then naturally drive the reaction in the forward direction from the major tautomeric form to the minor tautomeric form without needing any additional catalytic activity. We find that in this scenario the enzyme lowers the activation energy so much that there is no energy barrier left in the tautomerization, even if the quantum correlations quickly decay.
BACKGROUND: Key biological processes underlying health and disease-including electron transfer, redox regulation, and radical-mediated signaling-are fundamentally governed by quantum-mechanical principles. These processes are central to mitochondrial function, metabolism, and cellular signaling, yet their biomedical implications have remained difficult to address using classical computational approaches. RATIONALE: Recent advances in quantum computing, quantum sensing, and quantum machine learning enable direct simulation and measurement of quantum phenomena in biologically relevant systems. Hybrid quantum-classical algorithms, such as the Variational Quantum Eigensolver and Quantum Phase Estimation, now provide first-principles access to redox potentials, electronic couplings, and spin-dependent reactions that are directly linked to disease mechanisms. These developments establish the foundation for quantum biomedicine as a translational framework bridging molecular physics and clinical medicine. CONTENT: This review synthesizes current progress in the application of quantum technologies to biomedicine, emphasizing translational relevance. We discuss quantum-informed modeling of cancer metabolism and redox rewiring, protein misfolding in neurodegenerative diseases, immune and inflammatory signaling, infectious disease mechanisms, and drug discovery. We further propose a Quantum-Experimental-Clinical (QEC) pipeline that integrates quantum simulations with experimental validation and multi-omics clinical data, enabling mechanistic interpretation of disease phenotypes and identification of redox- and spin-sensitive therapeutic targets. CONCLUSION: Quantum biomedicine introduces a new mechanistic layer that links electronic-scale processes to clinical phenotypes. While current implementations are constrained by NISQ-era hardware, rapid advances in quantum algorithms and sensing technologies position quantum approaches as emerging tools in precision and translational medicine. Strategic integration of quantum methods with experimental and clinical workflows may accelerate biomarker discovery and therapeutic development. KEY POINTS: Quantum biomedicine redefines life as a dynamic equilibrium sustained by quantum coherence, tunnelling and redox resonance. Hybrid quantum-classical algorithms, such as VQE and QPE, enable first-principles modelling of redox and spin-dependent reactions with near-experimental accuracy. NISQ-era hardware supports proof-of-concept simulations of electron tunnelling and radical-pair dynamics, bridging computation with measurable biophysics. Integration of quantum simulations with spectroscopy and cryo-EM establishes a quantum-experimental-clinical (QEC) pipeline linking theory, experiment and medicine. Ethical, educational and governance frameworks are essential for equitable, transparent and sustainable implementation of quantum health technologies.